EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Establishing a nanoluciferase-based assay as a high-throughput screening platform for therapeutics in congenital nephrotic syndrome

Haruki Tsuhako, Mary Ann Suico, Haruka Kojima, Saki Takahashi, Shunsuke Tanigawa, Misato Kamura, Ryoichi Sato, Riko Kato, Aimi Owaki, Ryuichi Nishinakamura, Tsuyoshi Shuto, Hirofumi Kai

Journal of Pharmacological Sciences · 2025

DOI: 10.1016/j.jphs.2025.09.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacological Sciences, 2025. Verfasst von Haruki Tsuhako und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Membrane Proteins, Nephrotic Syndrome, High-Throughput Screening Assays, Luciferases. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology, Kumamoto University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nephrin is crucial for the formation of the glomerular slit diaphragm, which is the final filtration barrier in the kidney. A mutation in the NPHS1 gene that codes for nephrin causes congenital nephrotic syndrome of the Finnish type (CNF). Most missense mutations render nephrin non-functional due to the defective nephrin trafficking to the cell membrane. Pharmacological approaches that induce the expression of nephrin on the cell membrane are feasible, but therapeutic development is hampered by the lack of a high-throughput screening (HTS) system. Here, we developed a nanoluciferase HiBiT-based HTS platform to quantify the cell membrane expression of a nephrin mutant. This evaluation system reflected the previously reported results of various nephrin mutant localization. Using this system, we screened and identified 10 compounds that promoted the expression of the nephrin E725D mutant on the cell membrane. Moreover, the phosphorylation and N-glycosylation of nephrin, which are modifications that indicate its cell surface localization, correlated with the luminescence values of HiBiT-Nephrin in the compound screening. Consequently, this HiBiT-Nephrin evaluation system could be a new platform for predicting the pathogenicity of variants and searching for therapeutic agents for CNF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane ProteinsNephrotic SyndromeHigh-Throughput Screening AssaysLuciferasesHumansCell MembranePhosphorylationGlycosylationDrug Evaluation, PreclinicalMutationMutation, Missense

Stichwörter der Autor:innen

Compound screeningCongenital nephrotic syndromeHiBiT extracellular detection systemNephrinNephrin missense mutants

Substanzen

Membrane ProteinsnephrinLuciferases

Autor:innen und Institutionen

  • Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto,…
  • Department of Kidney Development, Institute of Molecular Embryology and Genetics, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Ministry of Education, Culture, Sports, Science and Technology
  • Kumamoto University
  • Japan Agency for Medical Research and Development

Zitieren

APA

Tsuhako, H., Suico, M. A., Kojima, H., Takahashi, S., Tanigawa, S., Kamura, M., Sato, R., Kato, R., Owaki, A., Nishinakamura, R., Shuto, T., & Kai, H. (2025). Establishing a nanoluciferase-based assay as a high-throughput screening platform for therapeutics in congenital nephrotic syndrome. Journal of Pharmacological Sciences. https://doi.org/10.1016/j.jphs.2025.09.006

Vancouver

Tsuhako H, Suico MA, Kojima H, Takahashi S, Tanigawa S, Kamura M, et al. Establishing a nanoluciferase-based assay as a high-throughput screening platform for therapeutics in congenital nephrotic syndrome. Journal of Pharmacological Sciences. 2025. doi:10.1016/j.jphs.2025.09.006

BibTeX
@article{Tsuhako2025,
  author = {Tsuhako, Haruki and Suico, Mary Ann and Kojima, Haruka and Takahashi, Saki and Tanigawa, Shunsuke and Kamura, Misato and Sato, Ryoichi and Kato, Riko and Owaki, Aimi and Nishinakamura, Ryuichi and Shuto, Tsuyoshi and Kai, Hirofumi},
  title = {Establishing a nanoluciferase-based assay as a high-throughput screening platform for therapeutics in congenital nephrotic syndrome},
  journal = {Journal of Pharmacological Sciences},
  year = {2025},
  doi = {10.1016/j.jphs.2025.09.006}
}
Kostenlos starten →